The NCCN’s updated guidelines for the treatment of breast cancer include updates on sentinel lymph node biopsy, ovarian function suppression, and the use of prognostic tools.

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for ...

New NCCN guidelines recognize the utility of MammaPrint for guiding anthracycline therapy selection in HR+/HER2- early-stage ...

US biotech Gilead Sciences today announced that its Trodelvy (sacituzumab govitecan-hziy) has now been added to the National ...

In a significant shift for the treatment landscape of essential thrombocythemia (ET), the US National Comprehensive Cancer Network (NCCN) has designated ropeginterferon alfa-2b-njft (Besremi) as a ...

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles ...

PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

Panelists discuss how payer coverage restrictions often conflict with NCCN guidelines for BTK inhibitor therapies in CLL, impeding evidence-based care. Panelists discuss how payer coverage often ...

The NCCN Guidelines in Practice™ helps busy health care professionals earn credits toward maintaining licensure and board certification while applying immediate, evidence-based updates to their ...